{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=76",
    "query": {
      "condition": "Metastatic Skin Cancer",
      "page": 76
    },
    "page_size": 10
  },
  "pagination": {
    "page": 76,
    "page_size": 10,
    "total_count": 2840,
    "total_pages": 284,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=77&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=75&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T18:43:52.452Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04740918",
      "title": "A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab Emtansine",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2021-06-07",
      "completion_date": "2024-06-19",
      "has_results": true,
      "last_update_posted_date": "2025-08-08",
      "last_synced_at": "2026-11-19T18:43:52.452Z",
      "location_count": 1,
      "location_summary": "Redlands, California",
      "locations": [
        {
          "city": "Redlands",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04740918"
    },
    {
      "nct_id": "NCT02858869",
      "title": "Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Melanoma",
        "Mucosal Melanoma",
        "Ocular Melanoma",
        "Stage IV Non-Small Cell Lung Cancer",
        "Stage IV Skin Melanoma",
        "Melanoma of Unknown Primary"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stereotactic Radiosurgery",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2016-10-04",
      "completion_date": "2023-10-28",
      "has_results": true,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-11-19T18:43:52.452Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02858869"
    },
    {
      "nct_id": "NCT00006369",
      "title": "ERA-923 in Treating Postmenopausal Women With Metastatic Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ERA-923",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": null,
      "start_date": "2000-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-11-06",
      "last_synced_at": "2026-11-19T18:43:52.452Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006369"
    },
    {
      "nct_id": "NCT00707161",
      "title": "Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Surgical resection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2005-09",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2017-03-31",
      "last_synced_at": "2026-11-19T18:43:52.452Z",
      "location_count": 2,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00707161"
    },
    {
      "nct_id": "NCT02390427",
      "title": "Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Recurrent Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Taselisib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab emtansine",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nancy Lin, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2015-04-20",
      "completion_date": "2024-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-19T18:43:52.452Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02390427"
    },
    {
      "nct_id": "NCT02598427",
      "title": "Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2 Positive Untreated Metastatic Breast Cancer",
        "Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kimberly Blackwell",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2017-05-01",
      "completion_date": "2018-02-22",
      "has_results": false,
      "last_update_posted_date": "2018-02-28",
      "last_synced_at": "2026-11-19T18:43:52.452Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02598427"
    },
    {
      "nct_id": "NCT03213041",
      "title": "Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "Estrogen Receptor Positive",
        "HER2/Neu Negative",
        "Progesterone Receptor Negative",
        "Recurrent Breast Carcinoma",
        "Stage IV Breast Cancer",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-09-14",
      "completion_date": "2022-03-30",
      "has_results": true,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-11-19T18:43:52.452Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03213041"
    },
    {
      "nct_id": "NCT02009397",
      "title": "A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2012-02",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2021-11-22",
      "last_synced_at": "2026-11-19T18:43:52.452Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02009397"
    },
    {
      "nct_id": "NCT05660083",
      "title": "Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2-negative Breast Cancer",
        "Metastatic Breast Cancer",
        "Metaplastic Breast Carcinoma",
        "TNBC - Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "L-NMMA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2023-01-12",
      "completion_date": "2028-12-02",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-11-19T18:43:52.452Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Houston, Texas",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05660083"
    },
    {
      "nct_id": "NCT04177108",
      "title": "A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Ipatasertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 242,
      "start_date": "2019-11-25",
      "completion_date": "2023-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-03-27",
      "last_synced_at": "2026-11-19T18:43:52.452Z",
      "location_count": 31,
      "location_summary": "Mobile, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04177108"
    }
  ]
}